Reversal	reversal	O	O
of	of	O	O
central	central	O	O
benzodiazepine	benzodiazepine	S_chemical	O
effects	effects	O	O
by	by	O	O
flumazenil	flumazenil	S_chemical	O
after	after	O	O
intravenous	intravenous	O	O
conscious	conscious	O	O
sedation	sedation	O	O
with	with	O	O
diazepam	diazepam	S_chemical	O
and	and	O	O
opioids	opioids	S_chemical	O
:	:	O	O
report	report	O	O
of	of	O	O
a	a	O	O
double-blind	double-blind	O	O
multicenter	multicenter	O	O
study	study	O	O
.	.	O	O

The	the	O	O
Flumazenil	flumazenil	S_chemical	O
in	in	O	O
Intravenous	intravenous	O	O
Conscious	conscious	O	O
Sedation	sedation	O	O
with	with	O	O
Diazepam	diazepam	S_chemical	O
Multicenter	multicenter	O	O
Study	study	O	O
Group	group	O	O
II.The	ii.the	O	O
efficacy	efficacy	O	O
and	and	O	O
safety	safety	O	O
of	of	O	O
a	a	O	O
new	new	O	O
benzodiazepine	benzodiazepine	S_chemical	O
antagonist	antagonist	O	O
,	,	O	O
flumazenil	flumazenil	S_chemical	O
,	,	O	O
were	were	O	O
assessed	assessed	O	O
in	in	O	O
a	a	O	O
double-blind	double-blind	O	O
multicenter	multicenter	O	O
study	study	O	O
.	.	O	O

Flumazenil	flumazenil	S_chemical	O
(	(	O	O
mean	mean	O	O
dose	dose	O	O
,	,	O	O
0.76	0.76	O	O
mg	mg	O	O
)	)	O	O
or	or	O	O
placebo	placebo	O	O
(	(	O	O
mean	mean	O	O
dose	dose	O	O
,	,	O	O
8.9	8.9	O	O
ml	ml	O	O
)	)	O	O
was	was	O	O
administered	administered	O	O
intravenously	intravenously	O	O
to	to	O	O
130	130	O	O
and	and	O	O
67	67	O	O
patients	patients	O	O
,	,	O	O
respectively	respectively	O	O
,	,	O	O
who	who	O	O
had	had	O	O
been	been	O	O
given	given	O	O
diazepam	diazepam	S_chemical	O
in	in	O	O
conjunction	conjunction	O	O
with	with	O	O
an	an	O	O
opioid	opioid	S_chemical	O
(	(	O	O
fentanyl	fentanyl	S_chemical	O
,	,	O	O
meperidine	meperidine	O	O
,	,	O	O
or	or	O	O
morphine	morphine	S_chemical	O
)	)	O	O
for	for	O	O
the	the	O	O
induction	induction	O	O
and	and	O	O
maintenance	maintenance	O	O
of	of	O	O
intravenous	intravenous	O	O
conscious	conscious	O	O
sedation	sedation	O	O
for	for	O	O
diagnostic	diagnostic	O	O
or	or	O	O
therapeutic	therapeutic	O	O
surgical	surgical	O	O
procedures	procedures	O	O
.	.	O	O

The	the	O	O
group	group	O	O
assessable	assessable	O	O
for	for	O	O
efficacy	efficacy	O	O
comprised	comprised	O	O
122	122	O	O
patients	patients	O	O
treated	treated	O	O
with	with	O	O
flumazenil	flumazenil	S_chemical	O
and	and	O	O
64	64	O	O
patients	patients	O	O
given	given	O	O
placebo	placebo	O	O
.	.	O	O

After	after	O	O
5	5	O	O
minutes	minutes	O	O
,	,	O	O
80/115	80/115	O	O
(	(	O	O
70	70	O	O
%	%	O	O
)	)	O	O
flumazenil-treated	flumazenil-treated	O	O
patients	patients	O	O
,	,	O	O
compared	compared	O	O
with	with	O	O
21/63	21/63	O	O
(	(	O	O
33	33	O	O
%	%	O	O
)	)	O	O
placebo-treated	placebo-treated	O	O
patients	patients	O	O
,	,	O	O
were	were	O	O
completely	completely	O	O
awake	awake	O	O
and	and	O	O
alert	alert	O	O
,	,	O	O
as	as	O	O
indicated	indicated	O	O
by	by	O	O
a	a	O	O
score	score	O	O
of	of	O	O
5	5	O	O
on	on	O	O
the	the	O	O
Observer	observer	O	O
's	's	O	O
Assessment	assessment	O	O
of	of	O	O
Alertness/Sedation	alertness/sedation	O	O
Scale	scale	O	O
.	.	O	O

Ninety-five	ninety-five	O	O
percent	percent	O	O
of	of	O	O
patients	patients	O	O
in	in	O	O
each	each	O	O
group	group	O	O
who	who	O	O
attained	attained	O	O
a	a	O	O
score	score	O	O
of	of	O	O
5	5	O	O
at	at	O	O
the	the	O	O
5-minute	5-minute	O	O
assessment	assessment	O	O
showed	showed	O	O
no	no	O	O
loss	loss	O	O
of	of	O	O
alertness	alertness	O	O
throughout	throughout	O	O
the	the	O	O
180-minute	180-minute	O	O
assessment	assessment	O	O
period	period	O	O
.	.	O	O

Flumazenil-treated	flumazenil-treated	O	O
patients	patients	O	O
also	also	O	O
performed	performed	O	O
significantly	significantly	O	O
better	better	O	O
on	on	O	O
the	the	O	O
Finger-to-Nose	finger-to-nose	O	O
Test	test	O	O
and	and	O	O
the	the	O	O
recall	recall	O	O
of	of	O	O
pictures	pictures	O	O
shown	shown	O	O
at	at	O	O
the	the	O	O
5-minute	5-minute	O	O
assessment	assessment	O	O
.	.	O	O

Flumazenil	flumazenil	S_chemical	O
was	was	O	O
well	well	O	O
tolerated	tolerated	O	O
,	,	O	O
with	with	O	O
no	no	O	O
serious	serious	O	O
adverse	adverse	O	B_disease
effects	effects	O	I_disease
reported	reported	O	O
.	.	O	O

Thirty-nine	thirty-nine	O	O
(	(	O	O
30	30	O	O
%	%	O	O
)	)	O	O
of	of	O	O
flumazenil-treated	flumazenil-treated	O	O
patients	patients	O	O
,	,	O	O
compared	compared	O	O
with	with	O	O
17	17	O	O
(	(	O	O
25	25	O	O
%	%	O	O
)	)	O	O
of	of	O	O
placebo-treated	placebo-treated	O	O
patients	patients	O	O
had	had	O	O
one	one	O	O
or	or	O	O
more	more	O	O
drug-related	drug-related	O	O
adverse	adverse	O	O
experiences	experiences	O	O
.	.	O	O

The	the	O	O
most	most	O	O
common	common	O	O
adverse	adverse	O	B_disease
effects	effects	O	I_disease
were	were	O	O
nausea	nausea	O	B_disease
and	and	O	I_disease
vomiting	vomiting	O	S_disease
in	in	O	O
the	the	O	O
flumazenil	flumazenil	S_chemical	O
group	group	O	O
and	and	O	O
nausea	nausea	O	S_disease
and	and	O	O
injection-site	injection-site	O	O
pain	pain	O	S_disease
in	in	O	O
the	the	O	O
placebo	placebo	O	O
group	group	O	O
.	.	O	O

Flumazenil	flumazenil	S_chemical	O
was	was	O	O
found	found	O	O
to	to	O	O
promptly	promptly	O	O
reverse	reverse	O	O
sedation	sedation	O	O
induced	induced	O	O
by	by	O	O
diazepam	diazepam	S_chemical	O
in	in	O	O
the	the	O	O
presence	presence	O	O
of	of	O	O
opioids	opioids	S_chemical	O
.	.	O	O

